Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 8K |
| Gross Profit | 0 | 0 | -10M | 0 | -6M |
| Operating Income | -40M | -17M | -19M | -23M | -8M |
| EBITDA | -40M | 3M | -18M | -18M | -9M |
| Net Income | -39.7B | 3M | -18M | -18M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$10.54
+1.54% today
1Y Change
-15.68%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProMIS Neurosciences, Inc. (PMN) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $10.54 and down 15.7% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -922.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -922.2%, free cash flow -103345.2% with operating margin 0.0% and ROIC 3.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PMN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PMN Max Drawdown
-75.86%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PMN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.1K
FY Net Income
-$9.7M
+46.5% YoY
Free Cash Flow
-$9.4M
+44.5% YoY
Revenue Growth
+0.0%
EPS Growth
-922.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 8K |
| Gross Profit | 0 | 0 | -10M | 0 | -6M |
| Operating Income | -40M | -17M | -19M | -23M | -8M |
| EBITDA | -40M | 3M | -18M | -18M | -9M |
| Net Income | -39.7B | 3M | -18M | -18M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 13M | 13M | 8M | 21M |
| Total Assets | 9.2B | 19M | 14M | 9M | 22M |
| Total Liabilities | 10.4B | 2M | 10M | 11M | 15M |
| Shareholder Equity | -1M | 16M | 4M | -2M | 7M |
| Total Debt | 0 | 0 | 0 | 0 | 5M |
| Net Debt | -6M | -13M | -13M | -8M | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+44.6% YoY
Capital Expenditures
6K
-209.2% YoY
Free Cash Flow
9M
+44.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-933.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.